How have SKYE shares performed in 2023?

Skye Bioscience's stock was trading at $0.0162 at the beginning of 2023. Since then, SKYE shares have increased by 10,579.0% and is now trading at $1.73. View the best growth stocks for 2023 here .

Are investors shorting Skye Bioscience?

Skye Bioscience saw a drop in short interest in October. As of October 31st, there was short interest totaling 100 shares, a drop of 66.7% from the October 15th total of 300 shares. Based on an average daily volume of 7,100 shares, the days-to-cover ratio is presently 0.0 days. View Skye Bioscience's Short Interest .

How were Skye Bioscience's earnings last quarter?

Skye Bioscience, Inc. (OTCMKTS:SKYE) announced its earnings results on Monday, November, 13th. The company reported ($3.17) earnings per share (EPS) for the quarter.

How do I buy shares of Skye Bioscience?

Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Skye Bioscience Stock Price, News & Analysis (OTCMKTS:SKYE)

$1.73

+0.12 (+7.45%)

(As of 12/1/2023 ET)

Compare

Today's Range: $1.44
▼
$2.01
50-Day Range: $1.44
▼
$4.09
52-Week Range: $1.44
▼
$14.00

Volume: 10,680 shs
Average Volume: 6,136 shs
Market Capitalization: $6.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Financials Headlines SEC Filings Short Interest

About Skye Bioscience Stock (OTCMKTS:SKYE)

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

SKYE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SKYE Stock News Headlines

November 24, 2023 | americanbankingnews.com

Financial Survey: Skye Bioscience (OTCMKTS:SKYE) and Elite Pharmaceuticals (OTCMKTS:ELTP)

November 21, 2023 | finance.yahoo.com

Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit

December 1, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 20, 2023 | thetimes.co.uk

Skye McAlpine’s easy one-tray dinner recipes

November 10, 2023 | mirror.co.uk

Matthew Perry's ex co-star Ione Skye shares heartbreaking last texts with Friends actor

November 8, 2023 | morningstar.com

Skye Bioscience Inc Ordinary Shares SKYE

October 26, 2023 | msn.com

Skye Bioscience posts early-stage data for glaucoma therapy

October 25, 2023 | finance.yahoo.com

Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma

December 1, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

October 20, 2023 | finance.yahoo.com

CORRECTION: Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"

October 10, 2023 | thetimes.co.uk

Skye McAlpine’s cakes with carrot, sweet potato and pumpkin

October 1, 2023 | bbc.com

Heritage award for 89-year-old Skye ferry crossing

September 27, 2023 | finance.yahoo.com

Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial

September 5, 2023 | finance.yahoo.com

Skye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conference

August 14, 2023 | finance.yahoo.com

Skye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

July 13, 2023 | finance.yahoo.com

Skye Bioscience Receives Positive Safety Review for Final Cohort of Fully-Enrolled Phase 1 Study of SBI-100 Ophthalmic Emulsion

July 6, 2023 | msn.com

Skye Completes Production Of Cannabinoid Based Drug In Preparation For Glaucoma Clinical Trial

June 9, 2023 | travel.usnews.com

Isle of Skye

June 5, 2023 | finance.yahoo.com

Skye Bioscience to Present at LD Micro Invitational XIII

May 15, 2023 | finance.yahoo.com

Skye Bioscience Receives Positive Safety Review in First Multiple-Administration Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion

April 29, 2023 | finance.yahoo.com

Skye Bioscience, Inc. (SKYE) Stock Historical Prices & Data - Yahoo Finance

April 27, 2023 | finance.yahoo.com

Skye Bioscience Begins Dosing Phase 1 Fourth Cohort in Clinical Trial of Novel CB1R Agonist

April 19, 2023 | msn.com

Short Volatility Alert: Skye Bioscience

April 4, 2023 | finanznachrichten.de

Skye Bioscience, Inc.: Skye Bioscience Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic Emulsion

April 4, 2023 | finance.yahoo.com

Skye Bioscience Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic Emulsion

April 3, 2023 | finanznachrichten.de

Skye Bioscience, Inc.: Skye Bioscience's Novel Cannabinoid Derivative Reduces Pain in Animal Model; Results Published in Scientific Journal

March 15, 2023 | msn.com

Ethics Committee Approves Starting Multiple Ascending Dose Arm Of Phase 1 Study Of Cannabinoid Based Drug For Treatment Of Glaucoma

See More Headlines

Receive SKYE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Skye Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 12/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:SKYE
CUSIP: N/A
CIK: 1516551
Web: skyebioscience.com
Phone: (858) 410-0266
Fax: N/A
Employees: 11
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($10.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,480,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -546.87%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.11
Quick Ratio: 1.11

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.44 per share
Price / Book: 3.93

Miscellaneous

Outstanding Shares: 3,890,000
Free Float: 3,858,000
Market Cap: $6.73 million
Optionable: Not Optionable
Beta: 0.91

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Punit S. Dhillon B.A. (Age 43)
Executive Chairman, President, CEO & Secretary
Comp: $733.08k
Ms. Kaitlyn Melanie Arsenault CPA (Age 36)
Chief Financial Officer
Comp: $455.89k
Dr. Christopher G. Twitty Ph.D. (Age 50)
Chief Scientific Officer
Mr. Tu Diep M.Sc.
Chief Development Officer

Key Competitors

View All Competitors

SKYE Stock Analysis - Frequently Asked Questions

How have SKYE shares performed in 2023?: Skye Bioscience's stock was trading at $0.0162 at the beginning of 2023. Since then, SKYE shares have increased by 10,579.0% and is now trading at $1.73.
View the best growth stocks for 2023 here.
Are investors shorting Skye Bioscience?: Skye Bioscience saw a drop in short interest in October. As of October 31st, there was short interest totaling 100 shares, a drop of 66.7% from the October 15th total of 300 shares. Based on an average daily volume of 7,100 shares, the days-to-cover ratio is presently 0.0 days.
View Skye Bioscience's Short Interest.
How were Skye Bioscience's earnings last quarter?: Skye Bioscience, Inc. (OTCMKTS:SKYE) announced its earnings results on Monday, November, 13th. The company reported ($3.17) earnings per share (EPS) for the quarter.
How do I buy shares of Skye Bioscience?: Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:SKYE) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial